Pharmacogenetics of schizophrenia in real clinical practice: a clinical case
Open Access
- 15 December 2018
- journal article
- Published by IMA Press, LLC in Neurology, Neuropsychiatry, Psychosomatics
- Vol. 10 (4), 88-93
- https://doi.org/10.14412/2074-2711-2018-4-88-93
Abstract
Schizophrenia is a socially significant mental disorder characterized by early onset and high time and financial expenditure on treatment. The basic drugs in these patients are antipsychotics that are highly effective against the positive and negative symptoms of schizophrenia, but at the same time have a wide range of adverse reactions (ARs). The clinical effect and tolerability of antipsychotics are variable and depend on the characteristics of genetically determined mechanisms (transportation, biotransformation, and elimination).The paper describes a clinical case of a female patient with schizophrenia who has been noted to be unresponsive to antipsychotic therapy for some years after the onset of the disease. After pharmacogenetic testing, she was found to be homozygous for the nonfunctional allelic variant CYP2D6*4 (1934 G>A, rs3892097), which was the reason for the complete shutdown of isoenzyme 2D6 activity and the development of ARs in the use of initial doses of antipsychotic drugs, as well as for an increase in the severity of ARs with aggravation of psycho-producing symptoms with an even slow titration of the daily dose.Keywords
This publication has 10 references indexed in Scilit:
- New findings in pharmacogenetics of schizophreniaCurrent Opinion in Psychiatry, 2018
- UGT-mediated metabolism plays a dominant role in the pharmacokinetic behavior and the disposition of morusin in vivo and in vitroJournal of Pharmaceutical and Biomedical Analysis, 2018
- Identification of novel CYP4F2 genetic variants exhibiting decreased catalytic activity in the conversion of arachidonic acid to 20-hydroxyeicosatetraenoic acid (20-HETE)Prostaglandins, Leukotrienes & Essential Fatty Acids, 2018
- ABCB1 and CYP2D6 polymorphisms and treatment response of psychotic patients in a naturalistic settingHuman Psychopharmacology: Clinical and Experimental, 2017
- Pharmacogenetics of drug–drug interaction and drug–drug–gene interaction: a systematic review on CYP2C9, CYP2C19 and CYP2D6Pharmacogenomics, 2017
- The efficacy and safety of valproic acid medications with controlled active ingredient release in adults in real clinical practice from the position of pharmacokinetic and pharmacogenetic approachesNeurology, Neuropsychiatry, Psychosomatics, 2017
- Mechanisms of development of antipsychotic-induced metabolic disorders: pharmacogenetic aspectBulletin of Siberian Medicine, 2017
- Pharmacogenomics and Stratified MedicinePublished by Elsevier BV ,2014
- Genomics and Pharmacogenomics of SchizophreniaCNS Neuroscience & Therapeutics, 2010
- Identification of a null allele of CYP2C9 in an African–American exhibiting toxicity to phenytoinPharmacogenetics, 2001